PETNET to make, distribute Lillys molecular imaging agent

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, has entered into a commercial agreement with Eli Lilly that grants Siemens PETNET the right to manufacture and distribute Lilly’s molecular imaging agent that is currently under review by the FDA for PET imaging.

The Knoxville, Tenn.-based PETNET is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly’s molecular imaging agent in the U.S., should it be FDA approved. Additionally, should Lilly’s molecular imaging agent be approved in markets outside the U.S., the companies said they would consider expanding this commercial agreement to those markets as well.


Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.